Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

Background/purpose: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative therapy for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but advanced age with multiple comorbidities limits the eligibility for allo-HSCT. We conducted a retrospectiv...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sheng-Hsuan Chien, Ming Yao, Chi-Cheng Li, Ping-Ying Chang, Ming-Sun Yu, Cih-En Huang, Tran-Der Tan, Cheng-Hsien Lin, Su-Peng Yeh, Sin-syue Li, Po-Nan Wang, Yi-Chang Liu, Jyh-Pyng Gau
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Acute leukemia
Myelodysplastic syndrome
Elderly adult
Allogeneic hematopoietic stem cell transplantation
Charlson comorbidity index
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/861f791a07d1452aa885f018ffe5effc
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/861f791a07d1452aa885f018ffe5effc

Documents similaires